FI932336A0 - Inhibering av celladhesionprotein-kolhydratvaexelverkan - Google Patents

Inhibering av celladhesionprotein-kolhydratvaexelverkan

Info

Publication number
FI932336A0
FI932336A0 FI932336A FI932336A FI932336A0 FI 932336 A0 FI932336 A0 FI 932336A0 FI 932336 A FI932336 A FI 932336A FI 932336 A FI932336 A FI 932336A FI 932336 A0 FI932336 A0 FI 932336A0
Authority
FI
Finland
Prior art keywords
kolhydratvaexelverkan
inhibering
celladhesionprotein
Prior art date
Application number
FI932336A
Other languages
English (en)
Other versions
FI932336A (fi
Inventor
Brian Seed
Gerd Walz
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of FI932336A publication Critical patent/FI932336A/fi
Publication of FI932336A0 publication Critical patent/FI932336A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI932336A 1990-11-23 1993-05-21 Inhibering av celladhesionprotein-kolhydratvaexelverkan FI932336A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61831490A 1990-11-23 1990-11-23

Publications (2)

Publication Number Publication Date
FI932336A FI932336A (fi) 1993-05-21
FI932336A0 true FI932336A0 (fi) 1993-05-21

Family

ID=24477202

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932336A FI932336A0 (fi) 1990-11-23 1993-05-21 Inhibering av celladhesionprotein-kolhydratvaexelverkan

Country Status (16)

Country Link
US (5) US5801044A (fi)
EP (1) EP0640129A1 (fi)
JP (2) JPH06504619A (fi)
AU (1) AU656934B2 (fi)
BR (1) BR9106995A (fi)
CA (1) CA2097617A1 (fi)
CZ (1) CZ96893A3 (fi)
FI (1) FI932336A0 (fi)
HU (1) HUT64476A (fi)
IE (1) IE914075A1 (fi)
IL (1) IL100094A0 (fi)
MC (1) MC2324A1 (fi)
NO (1) NO931864L (fi)
NZ (1) NZ240646A (fi)
PT (1) PT99582A (fi)
WO (1) WO1992009293A1 (fi)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
HUT64476A (en) * 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
EP0521692A3 (en) * 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
ATE210452T1 (de) * 1992-10-02 2001-12-15 Alberta Res Council Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
AU753310B2 (en) * 1998-05-20 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Novel method for gene cloning
EP2270147B2 (en) * 1999-04-09 2020-07-22 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1438387A4 (en) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
AU2002340168A1 (en) * 2001-10-11 2003-06-17 Protein Design Labs Inc. Treatment of prostate cancer by inhibitors of ncam2
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
EP1539251A4 (en) * 2002-07-03 2009-02-25 Glycomimetics Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL DISEASES WITH ANGIOGENESIS
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
JPWO2005035740A1 (ja) * 2003-10-09 2006-12-21 協和醗酵工業株式会社 無血清馴化したゲノム改変細胞
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
EP1763533B1 (en) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Specific antagonist for both e- and p-selectins
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
JP5175190B2 (ja) * 2005-08-09 2013-04-03 グリコミメティクス， インコーポレイテッド シュードモナス由来のｐａ−ｉｌレクチン、ｐａ−ｉｉｌレクチンまたは両方のレクチンのグリコミメティック阻害剤
DK1934236T3 (da) 2005-09-02 2013-02-25 Glycomimetics Inc Heterobifunktionelle pan-selektininhibitorer
EP2455100A3 (en) * 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007117505A2 (en) * 2006-04-05 2007-10-18 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
WO2007112403A2 (en) * 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
CA2666103C (en) 2006-10-12 2014-02-18 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
JP5511390B2 (ja) * 2007-02-09 2014-06-04 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの置換体を有する糖模倣体の使用方法
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009126556A1 (en) * 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009132130A2 (en) * 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
CA2727788A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
EP2424544A1 (en) * 2009-05-01 2012-03-07 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
CN101921336B (zh) * 2009-06-11 2013-02-27 北京华大蛋白质研发中心有限公司 一种抗人α1酸性糖蛋白的单克隆抗体及其制备方法
CN102869784A (zh) 2010-04-07 2013-01-09 动量制药公司 高甘露糖聚糖
EP2576616A4 (en) 2010-05-27 2014-05-21 Merck Sharp & Dohme PROCESS FOR PREPARING ANTIBODIES WITH IMPROVED PROPERTIES
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
AU2012258907A1 (en) 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
JP6392773B2 (ja) 2012-12-07 2018-09-19 グリコミメティクス， インコーポレイテッド 造血細胞の動員のためにｅ−セレクチンアンタゴニストを使用する化合物、組成物および方法
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
LT3227310T (lt) 2014-12-03 2019-09-10 Glycomimetics, Inc. E-selektino ir cxcr4 chemokino receptorių heterobifunkciniai inhibitoriai
JP2019502727A (ja) 2016-01-22 2019-01-31 グリコミメティクス， インコーポレイテッド Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3091454A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7449390B2 (ja) 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
DE2621908A1 (de) * 1975-05-26 1976-12-09 Sandoz Ag Neues diagnostikum fuer maligne tumore
JPS53136586A (en) * 1977-05-02 1978-11-29 Ajinomoto Co Inc Preparation of llglutamic acidd*c* semialdehyde
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60123494A (ja) * 1983-12-08 1985-07-02 Rikagaku Kenkyusho シアル酸含有オリゴ糖およびその製造法
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0323802A3 (en) * 1987-12-24 1989-07-26 Sandoz Ag Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
DE68922806T2 (de) * 1988-03-11 1996-02-29 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
DE68927188T2 (de) * 1988-11-14 1997-04-24 Brigham & Womens Hospital Antikörper, spezifisch gegen elam-1 sowie deren verwendung
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
FR2654876B1 (fr) * 1989-11-23 1993-11-12 Commissariat A Energie Atomique Dispositif de charge de moyens d'accumulation d'energie electrique, muni de moyens permettant de maitriser cette charge.
EP0485532A1 (en) * 1990-04-27 1992-05-20 Biogen, Inc. Fucosyl transferases involved in adhesion molecule expression
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
HUT64476A (en) * 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
ATE338762T1 (de) * 1991-04-19 2006-09-15 Univ Leland Stanford Junior Zusammensetzungen und methoden für die verknüpfung von endothelzellen
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Also Published As

Publication number Publication date
US5723583A (en) 1998-03-03
EP0640129A4 (en) 1994-07-05
US5858983A (en) 1999-01-12
HU9301510D0 (en) 1993-10-28
CA2097617A1 (en) 1992-05-23
NO931864D0 (no) 1993-05-21
NO931864L (no) 1993-07-21
US6613746B1 (en) 2003-09-02
IL100094A0 (en) 1992-08-18
WO1992009293A1 (en) 1992-06-11
FI932336A (fi) 1993-05-21
JPH06504619A (ja) 1994-05-26
EP0640129A1 (en) 1995-03-01
US6156881A (en) 2000-12-05
IE914075A1 (en) 1992-06-03
US5801044A (en) 1998-09-01
CZ96893A3 (en) 1993-12-15
JP2000325092A (ja) 2000-11-28
PT99582A (pt) 1992-10-30
AU656934B2 (en) 1995-02-23
HUT64476A (en) 1994-01-28
AU9061891A (en) 1992-06-25
NZ240646A (en) 1994-01-26
BR9106995A (pt) 1993-08-24
MC2324A1 (fr) 1994-01-18

Similar Documents

Publication Publication Date Title
FI930886A (fi) Foerfarande foer hindrande av avstoetning av transplanterad vaevnad
FI932336A (fi) Inhibering av celladhesionprotein-kolhydratvaexelverkan
FI930848A0 (fi) Foerfarande foer separering av ilmenit
FI931357A0 (fi) Framstaellning av polyhydroxifettsyraamider i naervaro av loesningsmedel
FI923931A (fi) Anordning foer granskning av insidan av en foergrenad roerlinje
FI930165A (fi) Framstaellning av synnerligen aktiva tvaettmedelspartiklar
FI931355A0 (fi) Fasoeverfoeringsmedierat foerfarande foer framstaellning av glukamidtvaettmedel
FI931356A0 (fi) Foerbaettrat katalytiskt foerfarande foer framstaellning av glukamidtvaettmedel
FI925805A0 (fi) Framstaellning av kompositmaterial
FI925609A (fi) Foerfarande foer framstaellning av sykliska sulfater
FI931879A (fi) Framstaellning av en peroxosyra
FI923779A (fi) Foerbaettringar i tillverkningen av nylongarn
FI931534A (fi) Foerfarande foer foerbaettring av aktiveringen av hydrauliskt masugns slagg foer framstaellning av byggnadsmaterial
FI930034A (fi) Foerfarande foer framstaellning av avlaongt foeremaol
FI925544A (fi) Bensoesyraderivat foer behandling av leukotrienassocierade sjukdomar
FI925546A (fi) Amidkopplade pyridylbensoesyraderivat foer behandling av leukotrien-associerade sjukdomar
FI930013A (fi) Hormonderivat av bakre hypofysloben
FI930123A0 (fi) Foerfarande foer anvaendning av oxiderade lipoproteiner i virusartade infektioner
FI924154A (fi) Foerfarande foer framstaellning av penem-estrar
FI932198A (fi) Anordning foer skydd av kondensorroer
FI932901A0 (fi) Foerfarande foer framstaellning av alkalimonofluorfosfat
FI923795A (fi) Kretselement foer aostadkommande av en spaerrspaenning foer kopplinsdioder
FI88315C (fi) Foerfarande foer blekning av cellulosamassa
FI931939A0 (fi) Foerfarande foer enzymatisk bestaemning av aldoser
FI924601A (fi) Foerbaettrat iontoforetiskt administrationssaett av laekemedel

Legal Events

Date Code Title Description
FD Application lapsed